Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes, Hypoglycemia, Renal Dysfunction, Insulin Dosing
Interventions
Not listed
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 99 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
Conditions
Type 1 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 17 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Completed Phase 4 Interventional Results available

Afrezza® Dosing Optimization Study

NCT04849845
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Afrezza Dose 1, Afrezza Dose 2
Combination Product
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Escondido, California • Walnut Creek, California
Completed Phase 4 Interventional Results available

Perioperative Insulin Glargine Dosing Study

NCT00309465
Conditions
Diabetes, Surgery
Interventions
Lantus, Insulin
Drug · Other
Lead sponsor
Tamra Dukatz
Other
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Conditions
Type 2 Diabetes Mellitus
Interventions
CGMS with an insulin pump using rapid acting insulin
Device
Lead sponsor
Diabetes Care Center
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salinas, California
Completed Phase 4 Interventional Results available

Prandial Insulin Dosing in Hospitalized Patients

NCT01101867
Conditions
Diabetes, Admitting Hospital, Non-critically Ill
Interventions
Aspart fixed dose, Aspart flexible dose
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Results available

Control-IQ Technology in Individuals With Type 2 Diabetes

NCT05111301
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Austin, Texas
Completed Not applicable Interventional Results available

Feasibility Trial Using an Inpatient Insulin Dosing Calculator

NCT06206525
Conditions
Diabetes Mellitus, Type 2
Interventions
Initial insulin dosing calculator
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Seattle, Washington
Conditions
Type 1 Diabetes
Interventions
Predictive Hyperglycemia Minimization Algorithm, Predictive Hypoglycemia Minimization Algorithm
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
15 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Conditions
Diabetes Mellitus, Type 1 Diabetes
Interventions
Rapid-Acting Insulin, Long acting insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
7 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Insulin, Continuous glucose monitor (CGM)
Drug · Device
Lead sponsor
Jagdeesh Ullal
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Meal-Tagging App and Web-based Portal:, Fitness Tracker
Other · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Evening only administration of insulin glargine, Morning only administration of insulin glargine, split dose insulin glargine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetes, Medication Adherence, Technology, Insulin
Interventions
Not listed
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Not applicable Interventional

Closed Loop Context Aware AID

NCT06676657
Conditions
Type 1 Diabetes
Interventions
iPancreas automated insulin delivery system
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Diabetes Mellitus, Type 2
Interventions
U-500R
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Diabetes Mellitus, Type 1
Interventions
Meal-Tagging App, Fitness Tracker
Other · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Type II
Interventions
V-Go
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Completed Not applicable Interventional Results available

Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study

NCT05014789
Conditions
Diabetes Mellitus, Type 1
Interventions
Control-IQ technology 2.0
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
14 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Pramlintide + Insulin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Santa Ana, California • Washington D.C., District of Columbia • Hollywood, Florida + 14 more
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Encino, California • Fresno, California • Huntington Beach, California + 34 more